Solid Tumor, Adult — Expanded Access Programs
Overview
Right2Hope maintains a directory of 35 expanded access programs, clinical trials, and compassionate use pathways listed for Solid Tumor, Adult. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with solid tumor, adult programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 9 programs are currently active or recruiting, with the remaining 26 in other lifecycle stages. Sponsors actively running programs in this area include A2 Biotherapeutics Inc., Dragonfly Therapeutics, BioInvent International AB, Corbus Pharmaceuticals Inc., Crossignal Therapeutics, Inc., and others.
By recruiting status
Snapshot of where every Solid Tumor, Adult program currently sits in its lifecycle.
- Active / Recruiting9
- Inactive26
Top sponsors
Organisations running the most Solid Tumor, Adult programs in the directory.
- A2 Biotherapeutics Inc.3 programs
- Dragonfly Therapeutics2 programs
- BioInvent International AB1 program
- Corbus Pharmaceuticals Inc.1 program
- Crossignal Therapeutics, Inc.1 program
- Cybrexa Therapeutics1 program
- Cyclacel Pharmaceuticals, Inc.1 program
- DualityBio Inc.1 program
- Effector Therapeutics1 program
- EpicentRx, Inc.1 program
Solid Tumor, Adult programs (35)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on VS-7375 for Patients with KRAS G12D-Mutated Solid Tumors — Verastem, Inc.
- Study on KB707 for Treating Advanced Lung Cancer — Krystal Biotech, Inc.
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on ACTengine® IMA203/IMA203CD8 Alone or with Nivolumab for Treating Recurrent or Hard-to-Treat Solid Tumors — Immatics US, Inc.
- Study on AL3818 and Nivolumab for Treating Advanced Solid Tumors — Sarcoma Oncology Research Center, LLC
- Expanded Access Program for MNPR-101-DFO*-89Zr in Patients with Solid Tumor Cancer — Monopar Therapeutics
- Study of DECOY20 with or Without Tislelizumab in Patients with Advanced Solid Tumors — Indaptus Therapeutics, Inc
- Study on D-1553 for Patients with Advanced Solid Tumors — InventisBio Co., Ltd
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on CRB-701 for Treating Solid Tumors — Corbus Pharmaceuticals Inc.
- Study on FMC-376 for Patients with KRAS G12C Mutated Advanced Solid Tumors — Frontier Medicines Corporation
- Study on AdAPT-001 for Patients with Sarcoma and Hard-to-Treat Solid Tumors — EpicentRx, Inc.
- Study of BI-1206 with Pembrolizumab for Advanced Solid Tumors (KEYNOTE-A04) — BioInvent International AB
- Study on GV20-0251 Alone and with Pembrolizumab for Treating Solid Tumor Cancers — GV20 Therapeutics
- Study of HB0045 Injection for Patients with Advanced Solid Tumors — Shanghai Huaota Biopharmaceutical Co., Ltd.
- Study on HST-1011 Alone and with an Anti-PD1 Antibody for Advanced Solid Tumors — HotSpot Therapeutics, Inc
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on the Effects of CT3001 in Patients with Advanced Solid Tumors — Crossignal Therapeutics, Inc.
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on Fadraciclib for Patients with Advanced Solid Tumors and Lymphoma — Cyclacel Pharmaceuticals, Inc.
- Study on COAST Therapy for Advanced Solid Tumors and Prostate Cancer — Medical University of South Carolina
- First-in-Human Study of DB-1419 for Advanced or Metastatic Solid Tumors — DualityBio Inc.
- First-in-Human Study of ICT01 in Patients with Advanced Cancer — ImCheck Therapeutics
- Study on Neratinib and Valproate for Advanced Solid Tumors, Including Ras-Mutated Cancers — Virginia Commonwealth University
- Nous-209 Genetic Vaccine for Treating Certain Advanced Cancers with Genetic Instability — Nouscom SRL
- Study on the Safety and Early Effects of TYRA-300 in Advanced Bladder Cancer and Other Tumors with FGFR3 Gene Changes — Tyra Biosciences, Inc
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab — Linnaeus Therapeutics, Inc.
- Study on CBX-12 for Patients with Advanced or Metastatic Solid Tumors — Cybrexa Therapeutics
- Study of DF1001 in Patients with Advanced Solid Tumors — Dragonfly Therapeutics
- Study of DF9001 in Patients With Advanced Solid Tumors — Dragonfly Therapeutics
- Study on eFT226 for Patients with Certain Advanced Solid Tumors — Effector Therapeutics
- Study on Using PD-1 Blockade for Treating Locally Advanced Mismatch Repair Deficient Solid Tumors — Memorial Sloan Kettering Cancer Center
- Study on VT3989 for Patients with Metastatic Solid Tumors with NF2 Gene Mutations — Vivace Therapeutics, Inc
- Study on Nivolumab After Partially Matched Bone Marrow Transplant in Children and Adults with Sarcoma — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Solid Tumor, Adult to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.